Definitive Contract HHSN261200622024C
Award Date
9/29/06
Potential Completion Date
8/31/12
Potential Value
$11M
Federal Agency
National Cancer Institute
Awardee
Ash Stevens LLC
Ultimate Awardee
Not listed
NAICS Category
541940 - Veterinary Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Detroit, MI 48202, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Michigan for a Phase 1 pharmacokinetic and pharmacodynamic clinical study of a nitric oxide releasing aspirin compound, with a ceiling value of $26,194,881.00. The contract was awarded on February 15, 2003 with a completion date of February 17, 2011. It is a cost-no-fee contract and was not subject to a set-aside requirement. The contract appears to be related to the NCI's...
This federal contract was awarded by the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), to Starks Associates Inc., a for-profit subchapter S corporation based in Buffalo, New York. The contract, valued at $25,655,771.28, is for the non-GMP (non-good manufacturing practice) synthesis of compounds to support the NCI's drug development efforts. The award is a definitive, cost-plus-fixed-fee contract with a period of performance through December 24, 2013....
This is a $2,250,351.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Provid Pharmaceuticals Inc., a for-profit small business organization. The contract is for the MEDICINAL CHEMISTRY LEAD OPTIMIZATION, (PHASE II) SBIR TOPIC 198 research project under the Small Business Innovation Research (SBIR) program. The contract was awarded on August 31, 2005 and has an ultimate completion date of May 31, 2008. This contract is set aside for small...
This is a $6,101,176.11 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI) to Alchem Laboratories Corporation, a small business manufacturer, for the non-GMP synthesis of compounds to support drug development. The contract has a period of performance through September 2021. Alchem Laboratories Corporation is a custom research organization that performs specialized services including custom organic synthesis, current Good Manufacturing Practice (cGMP)...
This is a definitive federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Alchem Laboratories Corporation, a for-profit manufacturer of pharmaceutical ingredients. The $2,860,070.26 cost-plus-fixed-fee contract is for the manufacture of bulk chemicals and pharmaceutical ingredients to support preclinical and clinical studies. The contract has a completion date of June 4, 2022 and was set aside for small businesses. Alchem Laboratories is the prime contractor and...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This is a $5,623,209.67 cost-plus-award-fee contract awarded by the National Cancer Institute to Alchem Laboratories Corporation, a for-profit pharmaceutical manufacturer in Alachua, Florida. The contract is for the synthesis of non-GMP small molecule samples to support the National Cancer Institute's research. It has an ultimate completion date of September 30, 2012. Alchem Laboratories is also an awardee on several indefinite delivery vehicle (IDV) contracts with the National Cancer...
This is a $25,543,276.37 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the not-for-profit research organization Mriglobal (doing business as Midwest Research Institute). The contract is for the analysis of anti-cancer chemicals and pharmaceutical formulations. Mriglobal is a highly experienced federal contractor, holding several significant...
This is a Cost Plus Fixed Fee delivery order awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., by the National Cancer Institute (NCI). The contract has a 5-year base period and a ceiling value of $10,885,758.00. The contract is for the HNGR(310)FC GMP3 CAMPAIGN AND OCTET METHOD DEVELOPMENT project, which involves research, development, and production services to support NCI's biomedical research programs. As an NCI Federally Funded Research and Development Center...
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute, a civilian agency, to Buffalo Biolabs, LLC, a small business, for the development of anticancer agents under the Small Business Innovation Research (SBIR) program. The award amount is $1,496,764.00 and the period of performance is until October 31, 2014. The contract is a Phase II SBIR action, which indicates it is for the continued development and testing of a promising technology that was previously funded under a...